No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
EW240719P87500
- 1.44
- -0.31-17.71%
15min DelayClose Jul 19 15:59 ET
1.57High0.75Low
1.57Open1.75Pre Close11 Volume570 Open Interest87.50Strike Price1.12KTurnover369.93%IV0.51%PremiumJul 19, 2024Expiry Date1.00Intrinsic Value100Multiplier0DDays to Expiry0.44Extrinsic Value100Contract SizeAmericanOptions Type-0.6144Delta0.1190Gamma46.76Leverage Ratio-17.0843Theta-0.0001Rho-28.73Eff Leverage0.0033Vega
Intraday
- 5D
- Daily
News
Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?
Earnings Preview: EW to Report Financial Results Post-market on July 24
$Edwards Lifesciences(EW.US)$ is scheduled to release its financial results post-market on July 24. Earnings PreviewAnalysts estimate $Edwards Lifesciences(EW.US)$ to post revenue of USD1.65 billion
Med-tech and Healthcare Stocks With Upside During 2Q Earnings - Baird
Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions
Is Edwards Lifesciences Corporation (NYSE:EW) Worth US$87.3 Based On Its Intrinsic Value?
Key Insights Edwards Lifesciences' estimated fair value is US$70.02 based on 2 Stage Free Cash Flow to Equity Current share price of US$87.31 suggests Edwards Lifesciences is potentially 25%
Edwards Lifesciences: A Strategic Hold Amid Expansion and Anticipated Clinical Trials
Comments
Edwards Lifesciences' impressive ROCE history and its ability to generate high returns on increasing amounts of capital employed indicate strong fundamentals. This warrants further research into the stock despite it being more 'expensive' than before.
Edwards Lifesciences (NYSE:EW) Is Aiming To Keep Up Its Impressive ReturnsAnalysts reconfirmed revenue and earnings forecasts for Edwards Lifesciences, indicating no major change in business expectations following recent results. The price target increase suggests analysts believe the business's intrinsic value is improving.
Investors banking on Edwards Lifesciences' high P/E ratio might face a challenge as the firm's predicted market-aligned growth hints at a potential share price decline.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after market closed (gaps range from large to small):
Gap Ups
1. $Align Technology(ALGN.US$ - up 11.5%
2. $Textron(TXT.US$ - up 5.2%
3. $STMicroelectronics(STM.US$ - up 4.1%
4. $Lam Research(LRCX.US$ - up 3.9%
5. $RELX PLC(RELX.US$ - up 3.1%
6. $Royal Caribbean(RCL.US$ - up 3.1%
7. $Micron Technology(MU.US$ - up 3.1%
8. $Western Digital(WDC.US$ - up 2.9...
Gap Ups
1. $Align Technology(ALGN.US$ - up 11.5%
2. $Textron(TXT.US$ - up 5.2%
3. $STMicroelectronics(STM.US$ - up 4.1%
4. $Lam Research(LRCX.US$ - up 3.9%
5. $RELX PLC(RELX.US$ - up 3.1%
6. $Royal Caribbean(RCL.US$ - up 3.1%
7. $Micron Technology(MU.US$ - up 3.1%
8. $Western Digital(WDC.US$ - up 2.9...
+17
19
Pre-Market Stock Movers
Gapping up
$Align Technology(ALGN.US$
(The orthodontics company surged 14% after posting adjusted earnings late Wednesday of $2.22 per share for the second quarter, beating estimates of $2.03 per share, according to Refinitiv. Revenue for the quarter also topped estimates, and revenue guidance for the year was above analyst expectations.)
$Meta Platforms(META.US$
(The Facebook parent jumped ne...
Gapping up
$Align Technology(ALGN.US$
(The orthodontics company surged 14% after posting adjusted earnings late Wednesday of $2.22 per share for the second quarter, beating estimates of $2.03 per share, according to Refinitiv. Revenue for the quarter also topped estimates, and revenue guidance for the year was above analyst expectations.)
$Meta Platforms(META.US$
(The Facebook parent jumped ne...
17
Read more